These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 28415969)

  • 1. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 30-day readmission, antibiotics costs and costs of delay to adequate treatment of Enterobacteriaceae UTI, pneumonia, and sepsis: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Antimicrob Resist Infect Control; 2017; 6():124. PubMed ID: 29225798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study.
    Zilberberg MD; Nathanson BH; Sulham K; Shorr AF
    BMC Infect Dis; 2021 Feb; 21(1):159. PubMed ID: 33557769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Crit Care; 2016 Jul; 20(1):221. PubMed ID: 27417949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EUropean prospective cohort study on
    Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
    BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
    de Maio Carrilho CM; de Oliveira LM; Gaudereto J; Perozin JS; Urbano MR; Camargo CH; Grion CM; Levin AS; Costa SF
    BMC Infect Dis; 2016 Nov; 16(1):629. PubMed ID: 27809803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
    Igbinosa O; Dogho P; Osadiaye N
    Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
    Zilberberg MD; Shorr AF
    J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.
    Knight GM; Dyakova E; Mookerjee S; Davies F; Brannigan ET; Otter JA; Holmes AH
    BMC Med; 2018 Aug; 16(1):141. PubMed ID: 30111322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary Tract Infections and Surgical Site Infections due to Carbapenem-Resistant Enterobacteriaceae in Renal Transplant.
    Rodrigues Dos Santos BG; Amaral ES; Fernandes PF; Oliveira CM; Rodrigues JL; Perdigão Neto LV; Girão ES
    Transplant Proc; 2016; 48(6):2050-5. PubMed ID: 27569943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a bedside tool to predict the probability of drug-resistant pathogens among hospitalized adult patients with gram-negative infections.
    Lodise TP; Bonine NG; Ye JM; Folse HJ; Gillard P
    BMC Infect Dis; 2019 Aug; 19(1):718. PubMed ID: 31412809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
    BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
    Torres-Gonzalez P; Cervera-Hernandez ME; Niembro-Ortega MD; Leal-Vega F; Cruz-Hervert LP; García-García L; Galindo-Fraga A; Martinez-Gamboa A; Bobadilla-Del Valle M; Sifuentes-Osornio J; Ponce-de-Leon A
    PLoS One; 2015; 10(10):e0139883. PubMed ID: 26431402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
    Li C; Li Y; Zhao Z; Liu Q; Li B
    J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
    Tabak YP; Sung AH; Ye G; Vankeepuram L; Gupta V; McCann E
    J Hosp Infect; 2019 May; 102(1):37-44. PubMed ID: 30503367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital mortality and length of stay associated with
    Cooper L; Yu K; Van Benten K; Patkar A; Ye G; Gregory S; Ai C; Gupta V
    Microbiol Spectr; 2024 Aug; 12(8):e0040224. PubMed ID: 38953323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Asakura T; Ikeda M; Nakamura A; Kodera S
    Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant
    Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
    Front Public Health; 2022; 10():983174. PubMed ID: 36091556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.